Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Bevacizumab Following TARE in Unresectable HCC
NCT06040099Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Feb 2024; status: active, not recruiting.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06040099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040099.